Affordable Access

deepdyve-link
Publisher Website

Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.

Authors
  • Pellegrini, Kathryn L1, 2
  • Sanda, Martin G1, 2
  • Patil, Dattatraya1, 2
  • Long, Qi2, 3, 4
  • Santiago-Jiménez, María5
  • Takhar, Mandeep5
  • Erho, Nicholas5
  • Yousefi, Kasra5
  • Davicioni, Elai5
  • Klein, Eric A6
  • Jenkins, Robert B7
  • Karnes, R Jeffrey8
  • Moreno, Carlos S2, 4, 9
  • 1 Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
  • 2 Winship Cancer Institute, Atlanta, GA, USA.
  • 3 Department of Biostatistics and Epidemiology and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • 4 Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA.
  • 5 GenomeDx Biosciences, Vancouver, BC, Canada. , (Canada)
  • 6 Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • 7 Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
  • 8 Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • 9 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Type
Published Article
Journal
British Journal of Urology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jun 01, 2017
Volume
119
Issue
6
Pages
961–967
Identifiers
DOI: 10.1111/bju.13779
PMID: 28107602
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis. Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96-7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16-19.83; P < 0.001). The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer. © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times